Table 3.
Multivariate analysis of Cox proportional hazards model 5-year of OS and PFS for all the enrolled patients (n = 424)
| Prognostic factors | OS | PFS | ||||
|---|---|---|---|---|---|---|
| Hazard ratio | 95 % CI | p value | Hazard ratio | 95 % CI | p value | |
| LMR: high versus low | 0.337 | 0.129–0.543 | 0.001 | 0.239 | 0.236–0.593 | 0.001 |
| HPV DNA status: HR-positive HPV DNA versus non-HR HPV DNA | 0.243 | 0.036–0.535 | 0.001 | 0.267 | 0.054–0.772 | 0.006 |
| Age: ≤46 versus >46 | 1.591 | 1.021–3.627 | 0.065 | 2.512 | 1.001–3.872 | 0.091 |
| FIGO classification: IIA versus IIB versus IIIA versus IIIB versus IIIB versus IVA | 3.486 | 0.957–5.248 | 0.035 | 3.275 | 0.845–5.328 | 0.073 |
| pathological type: SCC versus ADC versus ASC versus UDC | 2.523 | 1.093– 4.486 | 0.013 | 2.753 | 1.964–5.359 | 0.017 |
| Lymph node status classification: positive versus negative | 1.375 | 0.896–3.247 | 0.073 | 2.553 | 1.587–3.439 | 0.065 |
| Treatment modality: IC + RT versus CCRT versus IC + CCRT | 3. 864 | 3.587–6.339 | 0.039 | 2.486 | 1.987–4.239 | 0.102 |
| ALC: high versus low | 0.394 | 0.198–0.624 | 0.027 | 0.512 | 0.165–0.928 | 0.143 |
| AMC: high versus low | 1.703 | 0.138–3.614 | 0.181 | 0.982 | 0.301–2.124 | 0.713 |
OS overall survival; PFS progression-free survival; CI confidence interval; LMR lymphocyte-to-monocyte ratio; HPV human papillomavirus; DNA deoxyribonucleic acid; HR high risk; FIGO International Federation of Gynecology and Obstetrics; SCC squamous cell carcinoma; ADC adenocarcinoma; ASC adenosquamous carcinoma, UDC undifferentiated carcinoma; IC inductive chemotherapy; CCRT concurrent chemoradiotherapy; RT radiation therapy; AMC absolute monocyte count; ALC absolute lymphocyte count